

RIGHT Foundation: Mandate, Funding Model and Instruments to Fund Biomedical R&D

18 March, 2024

Hani Kim, PhD, MPH

Executive Director


RIGHT (Research Investment for Global Health Technology) Foundation



RIGHT
국제보건기술연구기금

RIGHT foundation: Korea's first non-profit organization dedicated to funding global health R&D

- Established in 2018 with the intent to engage Korean life science partners to develop and make available essential medical countermeasures *as global public goods*
- Supported by the Korean Ministry of Health and Welfare (MOHW), Bill & Melinda Gates Foundation and Korean life science companies
- Utilizes Korea's Official Development Assistance (ODA) to support R&D with the goal of contributing to global public health



Mission, Strategic Objectives, Investment Criteria

Investment Criteria:

- 1) Infectious diseases with a disproportionate burden in low- and middle-income countries (LMICs)
- 2) Unmet medical needs for new or improved health products in LMICs
- 3) Insufficient commercial incentives to drive R&D innovation
- 4) Opportunity to contribute Korea's strengths in R&D

MISSION: Alleviate the burden of infectious diseases that disproportionately affect the people in the low- and middle-income countries

STRATEGIC OBJECTIVES	#1 Product Development	#2 Collaboration	#3 Evidence Generation	#4 Training
	<p>Develop essential health technologies as global public good</p> <ul style="list-style-type: none">▪ Commit to global access▪ Aim for public procurement▪ Support technology transfer to enable local production	<p>Catalyze international Collaboration</p> <ul style="list-style-type: none">▪ Foster an exchange of knowledge and skills (i.e. co-develop)▪ Leverage Korea’s strengths (e.g. process optimization, engineering)	<p>Strengthen evidence base reflecting the LMIC context</p> <ul style="list-style-type: none">▪ Let the local context guide product development efforts▪ Learn <i>from</i> the LMIC partners	<p>Train work force in manufacturing essential health technologies</p> <ul style="list-style-type: none">▪ Support regional-level self-sufficiency in developing essential medical countermeasures (e.g. vaccines, biologics, diagnostics)

RIGHT's Funding Programs

	Product Development Award	Evidence Generation Award	Training Award
Objectives	<ul style="list-style-type: none"> Develop essential medical countermeasures as global public goods 	<ul style="list-style-type: none"> Strengthen evidence base reflecting the LMIC context 	<ul style="list-style-type: none"> Train work force in manufacturing essential medical countermeasures
Development Stage	<ul style="list-style-type: none"> From or near the initiation of the clinical development to regulatory approval and/or WHO prequalification 	<ul style="list-style-type: none"> n/a 	<ul style="list-style-type: none"> Basics for biopharmaceuticals and bioprocessing Vaccine manufacturing bioprocessing Regulatory process for biopharmaceuticals
Product Types	Vaccines, therapeutics/biologics, diagnostics		vaccines
Requirements	<ul style="list-style-type: none"> At least one Korean partner, 50% co-funding from applicants with a commercial partner 	<ul style="list-style-type: none"> Local institutions from the countries that the proposed activities focus on 	<ul style="list-style-type: none"> Individuals from LMICs holding positions related to vaccine manufacturing
Funding Amount & Duration	<ul style="list-style-type: none"> Up to 4 billion KRW/project (approximately 3.4M USD) for 3 years 	<ul style="list-style-type: none"> Up to 200 million KRW/project (approximately 165,000 USD, 1 yr) 	<ul style="list-style-type: none"> 3-week on-line and 5-week hands-on training in Korea including travel expenses and accommodation

Acknowledgements



보건복지부

Ministry of Health and Welfare

BILL & MELINDA
GATES foundation



Full
Partner

eu**bi**ologics



SD BIOSENSOR



SK bioscience



LG Chem

Associate
Partner

BIONEER
Innovation • Value • Discovery

nou
Beyond Diagnostics


QuadMedicine
SHAPE A WHOLE NEW WORLD